Fig. 2From: Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosisHRCT in a non-smoker patient with PPFE, who received nintedanib as only treatment, demonstrating progression of upper lobe fibrosis (A vs D and C vs F), as well as progression of “compensatory” emphysema in the right base (B vs E and C vs F)Back to article page